Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Of the three, SOUN is performing the worst on a year-to-date basis, down 27.8% in 2025. This could be mostly due to ...

Smile Doctors, the largest orthodontic support organization (OSO) in the U.S., ended 2024 strong, achieving organic YoY growth, the continued expansion of its Joint Venture model, entry into four new ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and developme ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 ...

Researchers found that gut microbiome composition is strongly linked to metabolic health across different life stages, with ...

Highlights,Bio-Rad Laboratories (BIO) drives innovation in life sciences and clinical diagnostics with a diversified product ...

On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 ...